ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. registers an AlphaScore of 42/100, indicating a neutral market stance in the healthcare sector on October 11, 2026. Important metrics provided include a gross margin of 99.34% and a net margin of -310.18%. A prominent strength is the exceptional revenue growth of 668.31%, which underpins a growth sub-score of 97. On the other hand, a major risk is reflected in its deep net losses and negative forward PE of -75.07, despite a positive return on equity of 70.21%. Evidence is constrained to the provided data record.

Written 11/10/2026, 00:38:35 UTC · Snapshot 11/10/2026